Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-BCMA dual nanobody-based CAR-T cells
- Development stage
- Unknown
- Lead developer
- Peking University People's Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19-BCMA dual nanobody-based CAR-T cells is an experimental cellular immunotherapy designed for desensitization in patients with donor-specific antibodies (DSA) who are candidates for allogeneic hematopoietic stem cell transplantation. The therapy utilizes T cells engineered to express chimeric antigen receptors (CARs) that simultaneously target CD19, found on B cells, and B-cell maturation antigen (BCMA), found on plasma cells. By depleting both B cells and antibody-secreting plasma cells, the treatment aims to reduce or eliminate DSAs that would otherwise cause graft rejection or poor engraftment. This specific construct utilizes nanobody-based binding domains, which are smaller and potentially more stable than traditional single-chain variable fragments (scFvs).
- Other names
- CD19-BCMA dual-target CAR-T cellsCD-19-BCMA dual-target CAR-T cellsCD 19-BCMA dual-target CAR-T cellsCD19/BCMA dual nanobody CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CD19-BCMA dual nanobody-based CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-BCMA dual nanobody-based CAR-T cells.